You are being redirected to PESI Rehab...
Inattentive AD/HD in the DSM-5: Finding Consensus or Igniting Debate?
- Faculty:
- Kevin T. Blake, PhD, PLC,
- Duration:
- 1 Hour 50 Minutes
- Format:
- Audio and Video
- Copyright:
- Dec 31, 2015
- Product Code:
- ONL020475
- Brochure Code:
- ONLBINADSM-1 (B)
- Media Type:
- Digital Seminar
- Access:
- Never expires.
Description
The DSM-5® Outlines New Criteria for Inattentive AD/HD
The neurophysiology, symptoms, treatment methods, and medications for Inattentive ADD are markedly different, compared to the other types of AD/HD. Since patients with Inattentive AD/HD are not typically as disruptive as those with other types of AD/HD, this type is often misunderstood or goes unrealized by the mental health professional.
This 2-hour webinar introduces participants to the DSM-5® criteria and treatment options for Inattentive AD/HD. A thorough analysis of types and presentations provides an opportunity to discern where there is consensus among the professional community. Explore the debate surrounding Sluggish Cognitive Tempo (SCT) and receive an update on its status as a recognized disorder.
DSM®, DSM-IV-TR®, and DSM-5® are registered trademarks of the American Psychiatric Association. The American Psychiatric Association is not affiliated with nor endorses this seminar.
Course Content
A.The Development of the DSM-5®
1. Timeline
2. Important changes to AD/HD
B.Autism Spectrum Disorder and Inattentive AD/HD
C.One Type of AD/HD in the DSM-5®
1.How it manifests with development
2.“Crossovers”
3. Lifelong longitudinal studies of those with AD/HD
D.Types of Inattentive AD/HD
E.Comorbidities
1.Major Depression
2.Generalized Anxiety Disorder
3.Avoidant Disorder
4.Specific Learning Disorder
5.Central Auditory Processing Disorder (CAPD)
6.Dyslexia
F.Diagnosis
1.Rating scales
2.Collaterals
3.Questionnaires, semi-structured interviews, other tests
4.Medical rule-outs
5.Ruling out “feigned disability”
G.Treatment
1.Medication
2.Behavioral techniques
3.Adjusting educational setting
4.Treating comorbidities
a.Specific learning disorder
b.Anxiety
H.What About Sluggish Cognitive Tempo (SCT)?
1. The theories of Brown and Barkley
2.Symptoms
3.Prevalence based on age and gender
4.Executive function
5.Etiology
a.Genetics/neurophysiology
b.Environmental
6.Diagnosis and treatment
7.New names?
a.Blake
b.Barkley
Credits
Handouts
| File type | File name | Number of pages | |
|---|---|---|---|
| Presentation (1.5 MB) | Available after Purchase |
Faculty
Kevin T. Blake, PhD, PLC, Related seminars and products
KEVIN T. BLAKE, PhD, PLC, is a recognized national authority with over 20 years of experience working with Autism Spectrum Disorder, specific learning disorder, and AD/HD in adolescents and adults. His interest in these were spurred by his own struggles to overcome his specific learning disorder-Dyslexia with impairment in phonological processing, spelling, fluency, and comprehension, as well as severe unspecified sensorineural hearing loss. These diagnoses occurred during the first year of his doctoral program, when not much was known about adults with specific learning disorder.
As Dr. Blake struggled to understand his own specific learning disorder, he decided to make his life's work about the diagnosis and treatment of adults with ASD, specific learning disorder, and AD/HD. When he started his professional life, Dr. Blake was one of only a handful of professionals in the country with such a focus. Now he travels the country sharing his personal story and what he has learned about ASD, specific learning disorder, AD/HD, and other neurobiological disorders with professionals who work with these populations, individuals with these disorders, and their loved ones.
Dr. Blake has been a member of several state and national organizations, a facilitator for a Tucson support group for adults with AD/HD for several years, and a published author, with articles appearing in Attention!, LDA Newsbriefs, and Perspectives (of the International Dyslexia Association). He was also a member of the LEAD 2000 Congress that advised the United States Congress regarding uses faced by citizens with specific learning disorder in the 21st century.
Speaker Disclosures:
Financial: Dr. Kevin Blake receives a speaking honorarium and recording royalties from PESI, Inc. and TPN.Health. He is a stockholder of Johnson and Johnson, Inc. and Amgen, Inc. All relevant financial relationships with ineligible organizations have been mitigated.
Non-financial: Dr. Kevin Blake is an at-large board member of CHADD of Tucson. He is a member of Children and Adults with Attention Deficit Disorders (CHADD), the International Dyslexia Association (IDA), the Learning Disabilities Association of America (LDA), and the American Psychological Association (APA).
Additional Info
Program Information
Access for Self-Study (Non-Interactive) Access never expires for this product.Target Audience
Psychologists, Social Workers, Counselors, Marriage and Family Therapists, Alcoholism and Drug Abuse Counselors, Nurse Practitioners, Educators
Reviews
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|
Overall: 4
Total Reviews: 3
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.
Please wait ...